Update: We are now collecting Disclosures from all users who edit content. You will be prompted to update these when you next edit content or you can complete your disclosures at any time in your user profile. This has been reflected in an updated terms-of-use.

Lymphangitic carcinomatosis

Last revised by Dr Sonam Vadera on 02 May 2022

Lymphangitic carcinomatosis, or lymphangitis carcinomatosa, is the term given to tumor spread through the lymphatics of the lung and is most commonly seen secondary to adenocarcinoma.

The demographics will reflect that of the underlying malignancy (see below).

Clinical presentation is variable. Some patients experience dyspnea and abnormal pulmonary function tests early in the course of the disease, well before any radiographic abnormalities are evident, whereas others remain asymptomatic until much later 4.

Lymphangitic carcinomatosis is most commonly seen secondary to adenocarcinomas such as 5:

It can also be seen in numerous other primary cancers, e.g. laryngeal cancer, pancreatic cancer, etc. 

A helpful mnemonic for lymphangitic carcinomatosis is sometimes used for its common causes.

Spread into the lymphatics in most cases (except in bronchogenic adenocarcinoma) usually occurs following hematogenous seeding of the lungs, with subsequent lymphatic involvement 1,3. It may also occur by retrograde spread into the lymphatics from the mediastinal and hilar lymph nodes.

Both the peripheral lymphatics coursing in the interlobular septa and beneath the pleura, and the central lymphatics coursing in the bronchovascular interstitium are involved 2.

Histologically tumor is seen both within lymphatics and in the adjacent interstitium, with associated edema and desmoplasia 3,4.

Radiographic appearances can most easily be divided into those due to the involvement of the peripheral (interlobular septa) and central lymphatic system. Involvement may be diffusely of both, or predominantly of one compartment or the other 4. Distribution of changes is variable, but most are asymmetric and patchy 3. It is usually bilateral but may be unilateral, especially in cases of lung and breast cancer.

Unfortunately up to a quarter of patients with subsequently established lymphangitic carcinomatosis have normal chest x-rays 2. When abnormal, the most common finding is a reticulonodular pattern, with thickening of the interlobular septa which may resemble septal (Kerley B) lines.

CT, especially HRCT, is excellent at demonstrating both peripheral and central changes.

Typically the appearance is that of interlobular septal thickening, most often nodular and irregular, although smooth thickening may also sometimes be seen 1-4. This results in a prominent definition of the secondary pulmonary lobules, manifesting as tessellating polygons.

There could also be an alveolar filling pattern blending into more reticulation 5.

Thickening of the bronchovascular interstitium is usually irregular and nodular, with changes seen extending towards the hilum 4

The combination may give a characteristic "dot in box" appearance.

Additional HRCT findings include 2,4:

A helpful sign is that the overall lung and lobular architecture is preserved 1. In most cases, lymphangitic carcinomatosis progresses rapidly and patients deteriorate (see treatment and prognosis below), however in some cases changes may remain stable over considerable time 3. As such a 'stable' appearance when compared to previous imaging does not necessarily exclude the diagnosis.

  • increased avidity within the nodular interlobular septal thickening
    • PET-CT has a sensitivity of 86% and specificity of 100% 7

The detection sensitivity of focal pulmonary lymphangitic carcinomatosis close to a primary malignant tumor however may be low in FDG-PET 11.

Treatment is determined by the histology of the primary tumor, but in general, relies on systemic chemotherapy.

Prognosis of patients with lymphangitic carcinomatosis is poor, with approximately half of patients succumbing to their illness within a year of diagnosis 2,3. Occasionally, long-term survival is encountered 3.

It is thought to have been first described "literature" by Gabriel Andral (French physician) in 1948 in a case with primary uterine cancer 9. although term "lymphangitis carcinomatosa" is a term introduced by Troisier in 1873 to describe diffuse infiltration of the lymphatics of lungs by malignant cells 13.

Considerations include a differential for that of thickened interlobular septa, with common entities comprising of 1,3:

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Fig 1: distribution of lymphangitic carcinomatosis
    Drag here to reorder.
  • Case 1
    Drag here to reorder.
  • Case 2
    Drag here to reorder.
  • Case 3
    Drag here to reorder.
  • Case 4
    Drag here to reorder.
  • Case 5
    Drag here to reorder.
  • Case 6
    Drag here to reorder.
  • Case 7
    Drag here to reorder.
  • Case 8
    Drag here to reorder.
  • Case 9
    Drag here to reorder.
  • Case 10: on chest x ray
    Drag here to reorder.
  • Case 11: on chest x ray
    Drag here to reorder.
  • Case 12: on chest x ray
    Drag here to reorder.
  • Case 13: on chest x ray
    Drag here to reorder.
  • Case 14: local
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.